Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Cumberland Pharmaceuticals To Announce Second Quarter 2013 Financial Results On August 6, 2013

CPIX
Cumberland Pharmaceuticals To Announce Second Quarter 2013 Financial Results On August 6, 2013

NASHVILLE, Tenn., July 29, 2013 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (NASDAQ:CPIX) announced today that it will release its second quarter 2013 results after the market closes on Tuesday, August 6, 2013.  A conference call and live Internet webcast will be held on Tuesday, August 6, 2013, at 4:30 p.m. Eastern Time to discuss the results.

To participate in the call, please dial 877-303-1298 (for U.S. callers) or 253-237-1032 (for international callers).  A rebroadcast of the teleconference will be available for one week and can be accessed by dialing 855-859-2056 (for U.S. callers) or 404-537-3406 (for international callers).  The Conference ID for the rebroadcast is 24879662. The live webcast and rebroadcast can be accessed via Cumberland's website at http://investor.shareholder.com/cpix/events.cfm.

Cumberland Pharmaceuticals Inc. is a specialty pharmaceutical company focused on the acquisition, development and commercialization of branded prescription products. The Company's primary target markets include hospital acute care and gastroenterology. Cumberland's marketed products include Acetadote® (acetylcysteine) Injection for the treatment of acetaminophen poisoning, Caldolor® (ibuprofen) Injection, the first injectable treatment for pain and fever approved in the United States, and Kristalose® (lactulose) for Oral Solution, a prescription laxative. Cumberland is dedicated to providing innovative products that improve quality of care for patients. For more information on Cumberland, please visit the Company's website at www.cumberlandpharma.com.

SOURCE Cumberland Pharmaceuticals Inc.



Get the latest news and updates from Stockhouse on social media

Follow STOCKHOUSE Today